导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.16% | 1117/4773 |
| 近一周 | -2.70% | 2877/5462 |
| 近一月 | -4.32% | 2389/5421 |
| 近一季 | -5.52% | 1866/5209 |
| 近半年 | -3.02% | 2100/4920 |
| 近一年 | 7.84% | 1256/4366 |
| 近两年 | 73.92% | 897/2954 |
| 近三年 | 44.39% | 635/2253 |
| 成立以来 | 82.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.46% 1542/4961 |
16.03% 1607/5312 |
- - |
- - |
| 2025 | 31.98% 1203/4813 |
3.20% 1156/3635 |
3.01% 1204/4076 |
26.07% 1366/4524 |
-1.52% 2959/4813 |
| 2024 | 8.72% 1522/3463 |
-0.61% 1131/2808 |
-4.12% 1470/3014 |
14.36% 1994/3129 |
-0.23% 1354/3463 |
| 2023 | -5.81% 779/2656 |
6.16% 718/2280 |
-3.88% 946/2385 |
-3.31% 895/2515 |
-4.53% 1077/2655 |
| 2022 | -17.23% 565/2207 |
-10.90% 454/1919 |
2.93% 1239/2016 |
-10.25% 370/2113 |
0.56% 1486/2208 |
| 2021 | 7.64% 493/1822 |
-0.93% 408/1255 |
12.04% 349/1330 |
1.31% 454/1466 |
-4.29% 1478/1822 |
| 2020 | 33.18% 463/1250 |
-3.16% 293/1028 |
21.69% 227/1067 |
9.47% 647/1164 |
3.24% 933/1184 |
| 2019 | 39.43% 282/1092 |
27.27% 351/754 |
-6.84% 529/804 |
8.41% 65/850 |
8.48% 313/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.61% 325/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时中证500指数增强C VS. 长安沪深300非周期A(740101) |